- Home
- CDNA vs NBXG Comparison
CDNA vs NBXG Comparison
Compare CDNA & NBXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CDNA | NBXG |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CDNA | NBXG |
|---|---|---|
| Price | $27.77 | $16.02 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $28.00 | N/A |
| AVG Volume (30 Days) | ★ 866.7K | 235.9K |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $48,324,000.00 | N/A |
| Revenue This Year | $16.01 | N/A |
| Revenue Next Year | $11.31 | N/A |
| P/E Ratio | $557.00 | ★ N/A |
| Revenue Growth | ★ 18.93 | N/A |
| 52 Week Low | $10.96 | $12.32 |
| 52 Week High | $28.42 | $17.43 |
Technical Indicators
Market Signals| Indicator | CDNA | NBXG |
|---|---|---|
| Relative Strength Index (RSI) | 71.83 | 49.38 |
| Support Level | $14.59 | $14.99 |
| Resistance Level | N/A | $16.94 |
| Average True Range (ATR) | 1.39 | 0.55 |
| MACD | 0.39 | -0.09 |
| Stochastic Oscillator | 92.28 | 33.65 |
Price Performance
Historical ComparisonAbout CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
About NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in NextGen Companies.